Loading
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.
Uwe Haberkorn is Head of Nuclear Medicine at Heidelberg University Hospital and the German Cancer Research Center (DKFZ). His specialisms are nuclear medicine, FAP-targeted radiopharmaceuticals and theranostics, with a focus on the FAP and PSMA targets. His Heidelberg group invented the quinoline-based FAP inhibitor (FAPI) tracers, and his Journal of Nuclear Medicine paper reported 68Ga-FAPI PET/CT tracer uptake across 28 different kinds of cancer. The group also led early PSMA-617 and FAP-targeted radioligand therapy in humans, and his record links him to FAP-2286 and lutetium-177 vipivotide tetraxetan. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer | Journal of Nuclear Medicine | 2019 |
Shares Journal of Nuclear Medicine, A university cyclotron network with shared regulatory files for new tracers, European Association of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ.
Shares European Association of Nuclear Medicine, FAPI PET, FAP, Lutetium-177 vipivotide tetraxetan.
Shares FAP-2286 (177Lu / 68Ga), Heidelberg University Hospital / NCT / DKFZ, FAPI PET, FAP.
Shares Journal of Nuclear Medicine, European Association of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ, PSMA.
Shares Journal of Nuclear Medicine, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares A university cyclotron network with shared regulatory files for new tracers, FAP-2286 (177Lu / 68Ga), FAPI PET, FAP.
Shares A university cyclotron network with shared regulatory files for new tracers, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).